Crossject plummets after competitor's failed clinical trial
Crossject's stock drops 22% after a competitor's failed clinical trial.
Published 3sem1 source
Lire en français
≈ 15s
The fact
The injectable medical devices sector takes a hit, affecting several stocks.
Investors fear a shift in funding toward alternative solutions.
Click the link to read an article on the topic: